American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 32, Issue 1 , Pages 38-46 , January 2011

Improvement in smell and taste dysfunction after repetitive transcranial magnetic stimulation

  • Robert I. Henkin, MD, PhD

      Affiliations

    • The Taste and Smell Clinic, Washington, DC, USA
    • Corresponding Author InformationCorresponding author. Center for Molecular Nutrition and Sensory Disorders, 5125 MacArthur Blvd NW, #20, Washington, DC 20016, USA. Tel.: +1 202 364 4180; fax: +1 202 364 9727.
    • ,
  • Samuel J. Potolicchio Jr., MD

      Affiliations

    • Department of Neurology, George Washington University Medical Center, Washington, DC, USA
    • ,
  • Lucien M. Levy, MD, PhD

      Affiliations

    • Department of Radiology, George Washington University Medical Center, Washington, DC, USA

Received 14 July 2009

References 

  1. Henkin RI, Schechter PJ, Hoye RC, et al. Idiopathic hypogeusia with dysgeusia, hyposmia and dysosmia: a new syndrome. J Am Med Assoc. 1971;217:434–440
  2. Henkin RI. Disorders of taste and smell. JAMA. 1971;218:1946
  3. Henkin RI. Evaluation and treatment of human olfactory dysfunction. In:  English GM editors. Otolaryngology. vol 2:Philadelphia (PA): Lippincott; 1993;p. 1–86
  4. Henkin RI. Taste and smell disorders, human. In:  Adelman G,  Smith BH editor. Encyclopedia of neuroscience. 3rd ed.. Boston (MA): Birkhauser; 2004;
  5. Levy LM, Henkin RI. Physiologically initiated and inhibited phantosmia: cyclic, unirhinal, episodic, recurrent phantosmia revealed by brain fMRI. J Comput Assist Tomogr. 2000;24:501–520
  6. Henkin RI, Levy LM, Lin CS. Taste and smell phantoms revealed by functional magnetic resonance imaging (fMRI). J Comput Assist Tomogr. 2000;24:106–123
  7. Idiopathic hypogeusia, a new disease. JAMA. 1971;217:471–472
  8. Atkin-Thor E, Goddard BW, O'Nion J, et al. Hypogeusia and zinc depletion in chronic dialysis patients. Am J Clin Nutr. 1978;31:1948–1951
  9. Tomita H, Ishii T, Mikoshiba H, et al. Combined disorders of taste and smell. Otologia. 1981;27(Suppl 1):259–264
  10. Scott AE. Clinical characteristics of taste and smell disorders. Ear Nose Throat J. 1989;68:297–315
  11. Doty RL. Olfactory dysfunction in neurodegenerative disorders. In:  Getchell TV,  Doty RL,  Bartoshuk LM, et al. editor. Smell and taste in health and disease. New York (NY): Raven Press; 1991;p. 735–751
  12. Mott AE, Leopold DA. Disorders in taste and smell. Med Clin North Am. 1991;75:1321–1352
  13. Levy LM, Henkin RI, Hutter A, et al. Functional MRI of human olfaction. J Comput Assist Tomogr. 1997;21:849–856
  14. In:  Meiselman HL,  Rivlin RS editor. Human taste and smell: measurements and uses. New York (NY): MacMillan; 1986;
  15. Cain WS, Gent JS, Catalanotto FA, et al. Clinical evaluation of olfaction. Am J Otolaryngol. 1983;4:252–256
  16. Poellinger A, Thomas R, Liu P, et al. Activation and habituation in olfaction-an fMRI study. Neuroimage. 2001;13:547–560
  17. Youssem DM, Maldigian JA, Siddiqi F, et al. Gender effects on odor-stimulation functional magnetic imaging. Brain Res. 1999;868:480–487
  18. Henkin RI, Velicu I, Papathanassiu A. cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender and age. Am J Med Sci. 2007;334:431–440
  19. Henkin RI, Velicu I. Decreased parotid salivary cyclic nucleotides related to smell loss severity in patients with taste and smell dysfunction. Metabolism. 2009;58:1717–1723
  20. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus: relationships to taste and smell dysfunction, gender and age. Clin Invest Med. 2008;31:E71–E77
  21. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus related to severity of smell loss in patients with smell dysfunction. Clin Invest Med. 2008;31:E78–E84
  22. Henkin RI, Martin BM, Agarwal RP. Efficacy of exogenous zinc in treatment of patients with carbonic anhydrase VI deficiency. Am J Med Sci. 1999;318:392–404
  23. Henkin RI, Velicu I, Schmidt L. An open label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci. 2009;337:396–406
  24. Levy LM, Henkin RI. Brain GABA levels are decreased in patients with phantageusia and phantosmia demonstrated by magnetic resonance spectroscopy. J Comput Assist Tomogr. 2004;28:721–727
  25. Henkin RI, Potolicchio SJ, Levy LM. Rapid changes in taste and smell function following transcranial magnetic stimulation (TCMS) in humans: relationships to CNS plasticity. FASEB J. 2002;16:A875
  26. Werhahn KJ, Kunesch E, Noachtar S, et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol. 1999;517:591–597
  27. Cohen LG, Ziemann U, Chen R, et al. Studies of neuroplasticity with transcranial magnetic stimulation. J Clin Neurophysiol. 1998;15:305–324
  28. Zangen A, Hyodo K. Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens. Neuroreport. 2002;13:2401–2405
  29. Funamizu H, Ogiue-Ikeda M, Mukai H, et al. Acute repetitive transcranial magnetic stimulation reactive-dopaminergic system in lesion rats. Neurosci Lett. 2005;383:77–81
  30. Keck ME, Sillaber I, Ebner K, et al. Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. Eur J Neurosci. 2000;12:3713–3720
  31. Kanno M, Matsumoto M, Togashi H, et al. Effects of acute repetitive transcranial magnetic stimulation on extracellular serotonin concentration in the rat prefrontal cortex. J Pharmacol Sci. 2003;93:451–457
  32. Gur E, Lerner B, van de Kar LD, et al. Chronic rTMS induces subsensitivity of post-synaptic 5-HTIA receptors in rat hypothalamus. Int J Neuropsychopharmacol. 2004;7:335–340
  33. Ziemann U, Tergau F, Bruns D, et al. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr. Clin Neurophysiol/Electromyogr Motor Control. 1997;105:430–437
  34. Hallett M. Transcranial magnetic stimulation and the human brain. Nature. 2000;406:147–150
  35. Merabet LB, Theoret H, Pascual-Leone A. Transcranial magnetic stimulation as an investigative tool in the study of visual function. Optom Vis Sci. 2003;80:356–368
  36. Jahanshahi M, Rothwell J. Transcranial magnetic stimulation of cognition: an emerging field. Exp Brain Res. 2000;131:1–9
  37. Khedr EM, Ahmed MA, Fathy N, et al. Therapeutic trial of repetitive transcranial magnetic stimulation after acute ischemic stroke. Neurology. 2005;65:466–468
  38. Mally J, Stone TW. Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci. 1999;162:179–184
  39. De Ridder D, Verstraeten E, Van der Kelen K, et al. Transcranial magnetic stimulation for tinnitus: influence of tinnitus duration on stimulation parameter choice and maximal tinnitus suppression. Otol Neurotol. 2005;26:616–619
  40. Schechter PJ, Henkin RI. Abnormalities of taste and smell following head trauma. J Neurol Neurosurg Psychiatr. 1974;37:802–810
  41. Henkin RI, Larson AL, Powell RD. Hypogeusia, dysgeusia. hyposmia and dysosmia following influenza-like infection. Ann Otol Rhin Laryngol. 1975;84:672–682
  42. Henkin RI. Drug induced taste and smell disorders: incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Safety. 1994;11:310–377
  43. Henkin RI. Newer aspects of copper and zinc metabolism. In:  Mertz W,  Hopkins L editor. New trace metals and nutrition. New York (NY): Marcel Dekker; 1971;p. 255–311
  44. Henkin RI, Schecter PJ, Friedewald WT, et al. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci. 1976;272:285–299
  45. Boroojerdi B, Phipps M, Kopylev L, et al. Enhancing analogic reasoning with rTCMS over the left prefrontal cortex. Neurology. 2001;56:526–528
  46. Ziemann U, Lonnecker S, Steinhoff BJ, et al. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 1996;40:367–378
  47. Quartarone A, Morgante F. Long lasting effects of transcranial direct current stimulation on motor imagery. Neuroreport. 2004;15:1289–1291
  48. Wu T, Sommer M, Tergau F, et al. Lasting influence of repetitive transcranial magnetic stimulation on intracortical excitability in human subjects. Neuroscience Lett. 2000;287:37–40
  49. Di Lazzaro V, Oliviero A, Profice P, et al. Direct demonstration of intrahemispheric inhibition of the human motor cortex produced by transcranial magnetic stimulation. Exp Brain Res. 1999;124:520–524
  50. Strafella AP, Ko JH, Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage. 2006;31:1666–1672
  51. Strafella AP, Paus T, Fraraccio M, et al. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain. 2003;126:2609–2615
  52. Ziemann U, Hallet M, Cohen L. Mechanisms of deafferentation induced plasticity in human motor cortex. J Neurosci. 1998;18:7000–7007
  53. Ziemann U. TMS induced plasticity in human cortex. Rev Neurosci. 2004;15:53–266
  54. Kinecht S, Henningsen H, Hohling P, et al. Plasticity of plasticity? Changes in the pattern of perceptual correlates of reorganization after amputation. Brain. 1998;121:717–724
  55. Sandyk R. Treatment with AC pulsed electromagnetic fields improve olfactory function in Parkinson's disease. Int J Neurosci. 1999;97:225–233
  56. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder?. QJM. 1999;92:473–480
  57. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853–860
  58. Müller A, Reichmann H, Livermore A, et al. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm. 2002;109:805–811
  59. Burkhard PR, Landis BN. Parkinsonism: the hyposmia and phantosmia connection. Arch Neurol. 2009;66:539
  60. Juckel G, Mendlin A, Jacobs BL. Electrical stimulation of rat medial prefrontal cortex enhances forebrain serotonin output: implications for electroconvulsive therapy and transcranial magnetic stimulation in depression. Neuropsychopharmacology. 1999;21:391–398
  61. Betarbet R, Zigova T, Bakay RA, et al. Dopaminergic and gabaergic interneurons of the olfactory bulb are derived from the neonatal subventricular zone. Int J Dev Neurosci. 1996;14:921–930
  62. Panzanelli P, Homanics GE, Otterson OP, et al. Pre and post synaptic GABA a receptors at reciprocal dendrodendritic synapses in the olfactory bulb. Eur J Neurosci. 2004;20:2945–2951
  63. Brünig I, Sommer M, Hatt H, et al. Dopamine receptor subtypes modulate olfactory bulb γ-aminobutyric acid type a receptors. Proc Natl Acad Sci U S A. 1999;96:2456–2460
  64. Olianas MC, Onali P. GABAB receptor-mediated stimulation of adenylyl cyclase activity in membranes of rat olfactory bulb. Br J Pharmacol. 1999;126:657–664
  65. Okutani F, Yagi F, Kaba H. GABAergic control of olfactory learning in young rats. Neuroscience. 1999;93:1297–1300
  66. Nusser Z, Kay LM, Laurent G, et al. Disruption of GABAA receptors on GABAergic interneurons leads to increased oscillatory power in the olfactory bulb network. J Neurophysiol. 2001;86:2823–2833

PII: S0196-0709(09)00220-8

doi: 10.1016/j.amjoto.2009.10.001

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 32, Issue 1 , Pages 38-46 , January 2011

Article Tools